SBL
ABBV icon

Sargent Bickham Lagudis’s AbbVie ABBV Stock Holding History

Sargent Bickham Lagudis’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		$3.92M Buy
24,242
+27
+0.1% +$4.14K 0.32% 67
2022
Q3 		$3.25M Sell
24,215
-151
-0.6% -$21.7K 0.29% 78
2022
Q2 		$3.73M Sell
24,366
-2,172
-8% -$332K 0.32% 66
2022
Q1 		$4.3M Sell
26,538
-153
-0.6% -$22.2K 0.33% 63
2021
Q4 		$3.61M Buy
26,691
+129
+0.5% +$15.2K 0.27% 78
2021
Q3 		$2.87M Buy
26,562
+3,846
+17% +$439K 0.23% 88
2021
Q2 		$2.56M Sell
22,716
-220
-1% -$24.8K 0.21% 93
2021
Q1 		$2.48M Sell
22,936
-22
-0.1% -$2.35K 0.22% 87
2020
Q4 		$2.46M Buy
22,958
+123
+0.5% +$11.8K 0.23% 84
2020
Q3 		$2M Buy
22,835
+468
+2% +$44.1K 0.2% 86
2020
Q2 		$2.2M Sell
22,367
-1,069
-5% -$94.1K 0.24% 83
2020
Q1 		$1.79M Buy
23,436
+2,405
+11% +$205K 0.23% 85
2019
Q4 		$1.86M Sell
21,031
-235
-1% -$19.5K 0.21% 91
2019
Q3 		$1.61M Sell
21,266
-35
-0.2% -$2.4K 0.19% 96
2019
Q2 		$1.55M Sell
21,301
-562
-3% -$44.2K 0.18% 97
2019
Q1 		$1.76M Sell
21,863
-25,484
-54% -$2.08M 0.2% 95
2018
Q4 		$4.37M Buy
47,347
+1,051
+2% +$92.4K 0.56% 42
2018
Q3 		$4.38M Sell
46,296
-23
-0% -$2.18K 0.52% 48
2018
Q2 		$4.29M Buy
46,319
+1,271
+3% +$124K 0.53% 46
2018
Q1 		$4.26M Sell
45,048
-964
-2% -$106K 0.53% 44
2017
Q4 		$4.45M Buy
46,012
+1,264
+3% +$119K 0.53% 48
2017
Q3 		$3.98M Buy
44,748
+1,922
+4% +$146K 0.49% 52
2017
Q2 		$3.1M Sell
42,826
-6,049
-12% -$407K 0.4% 65
2017
Q1 		$3.19M Sell
48,875
-15,254
-24% -$959K 0.41% 67
2016
Q4 		$4.02M Buy
64,129
+63,318
+7,807% +$3.86M 0.62% 42
2016
Q3 		$4.44K Sell
811
-68,079
-99% -$4.41M 0.67% 37
2016
Q2 		$4.26M Sell
68,890
-2,895
-4% -$176K 0.66% 40
2016
Q1 		$4.1M Buy
+71,785
New +$4M 0.66% 38

Other funds holding ABBV

AWA
Arete Wealth Advisors Chicago, Illinois $1.33B AUM 25.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Sargent Bickham Lagudis's ABBV Position: Q4 2022 in Review

Sargent Bickham Lagudis increased its AbbVie (ABBV) stake by 0.11% in Q4 2022, buying an estimated $4.14K and bringing the position to 24,242 shares worth $3.92M. The position accounts for 0.32% of the portfolio, ranked #67.

Sargent Bickham Lagudis first reported a position in ABBV in Q1 2016 and has held it in 28 quarters since. The position peaked at $4.45M in Q4 2017. 3,167 funds tracked by Wall St. Rank hold ABBV as of Q4 2022.

  • Sargent Bickham Lagudis held 24,242 shares of AbbVie worth $3.92M as of Q4 2022.
  • Sargent Bickham Lagudis bought 27 AbbVie shares in Q4 2022, an estimated $4.14K.
  • AbbVie made up 0.32% of Sargent Bickham Lagudis's portfolio in Q4 2022, its #67 holding.
  • Sargent Bickham Lagudis first reported a position in AbbVie in Q1 2016 and has held it in 28 quarters since.
  • Sargent Bickham Lagudis's AbbVie position peaked at $4.45M in Q4 2017.
  • 3,167 funds tracked by Wall St. Rank held AbbVie as of Q4 2022.

Based on Sargent Bickham Lagudis's 13F filing for Q4 2022, filed 23 Jan 2023.